Drug intelligence / Profile preview

ARC-201

Development stage: Preclinical
Lead developer: Taiho Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

ARC-201 is a novel dual-TOP1i Antibody-Drug Conjugate (ADC) designed for the treatment of solid tumors. Developed by Araris Biotech, which was subsequently acquired by Taiho Pharmaceutical, this investigational drug targets NaPi2b (Solute Carrier Family 34 Member 2) and delivers an optimized Exatecan payload, a topoisomerase 1 inhibitor. The ADC is engineered with a stable payload attachment at a low Drug-to-Antibody Ratio (DAR) to maximize efficacy while managing Exatecan toxicity. Its mechanism of action involves the targeted delivery of the cytotoxic TOP1i to cancer cells expressing NaPi2b, leading to DNA damage and cell death. ARC-201 is currently in the preclinical stage of development.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on ARC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC-201.

Explore the full profile